SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Stock Information for Trevena Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Trevena Inc.

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
SCYNEXIS Announces $40.0 Million Private Placement
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.